Livre : Nouvel Ordre Mondial
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Top Albums (17/09/2021 - 24/09/2021)
Top Albums (17/09/2021 - 24/09/2021) Pos. SD Artiste Titre Éditeur Distributeur 1 FLORENT PAGNY L'AVENIR CAPITOL MUSIC FRANCE UNIVERSAL MUSIC FRANCE 2 LETO 17% REC118 WARNER MUSIC FRANCE 3 1 JOHNNY HALLYDAY JOHNNY ACTE II LABEL PANTHEON UNIVERSAL MUSIC FRANCE 4 2 SOPRANO CHASSEUR D'ETOILES REC118 WARNER MUSIC FRANCE 5 3 OBOY NO CRARI BELIEVE BELIEVE 6 LIL NAS X MONTERO SONY MUSIC ENTERTAINMENT 7 4 GRAND CORPS MALADE MESDAMES CAROLINE FRANCE UNIVERSAL MUSIC FRANCE 8 9 LAYLOW L'ÉTRANGE HISTOIRE DE MR.ANDERSON SONY MUSIC ENTERTAINMENT SONY MUSIC ENTERTAINMENT 9 6 JUL DEMAIN ÇA IRA BELIEVE BELIEVE 10 5 IRON MAIDEN SENJUTSU WEA WARNER MUSIC FRANCE 11 7 DRAKE CERTIFIED LOVER BOY ISLAND DEF JAM 12 13 NEKFEU LES ÉTOILES VAGABONDES : EXPANSION POLYDOR UNIVERSAL MUSIC FRANCE 13 14 CLARA LUCIANI C?UR ROMANCE MUSIQUE UNIVERSAL MUSIC FRANCE 14 8 IMAGINE DRAGONS MERCURY - ACT 1 POLYDOR UNIVERSAL MUSIC FRANCE 15 15 DADJU POISON OU ANTIDOTE POLYDOR UNIVERSAL MUSIC FRANCE 16 17 DAMSO QALF TRENTE-QUATRE CENTIMES 17 18 PNL DEUX FRERES BELIEVE BELIEVE 18 19 THE WEEKND THE HIGHLIGHTS ISLAND DEF JAM UNIVERSAL MUSIC FRANCE 19 12 BILLIE EILISH HAPPIER THAN EVER POLYDOR UNIVERSAL MUSIC FRANCE 20 20 NINHO DESTIN REC. 118 / MAL LUNE MUSIC WARNER MUSIC FRANCE 21 16 NAPS LES MAINS FAITES POUR L'OR BELIEVE BELIEVE 22 21 DOJA CAT PLANET HER (DELUXE) SONY MUSIC ENTERTAINMENT 23 22 NINHO M.I.L.S. 3 REC. 118 / MAL LUNE MUSIC WARNER MUSIC FRANCE 24 23 DUA LIPA FUTURE NOSTALGIA WEA WARNER MUSIC FRANCE 25 28 SCH JVLIVS II REC118 WARNER MUSIC FRANCE 26 29 DJADJA & DINAZ SPLEEN BELIEVE BELIEVE Classements officiels de la Société Civile des Producteurs Phonographiques (SCPP) établis par GFK en collaboration avec le SNEP. -
DP Bilan 2020.Indd
LA PRODUCTION MUSICALE FRANÇAISE EN 2020 Décryptage d’une année pas comme les autres snep 2020 : UNE CROISSANCE ENTRAVÉE PAR LA CRISE SANITAIRE mais un business model résistant Après 4 ans de résultats positifs, le marché 2020 stoppé la dynamique retrouvée depuis 5 ans mais l’ont de la musique enregistrée en France reste stable à néanmoins freinée. 781 M€, preuve de la solidité de son modèle économique qui a su tenir le cap malgré un contexte complètement Tout au long de cette année atypique, la consommation bouleversé par la crise sanitaire. et donc les revenus de la musique, ont subi les L’arrêt total des concerts et des festivals depuis mars conséquences de la pandémie. L’écart entre la dernier, des sorties reportées, des plans de promotion progression du streaming et le recul des ventes physiques bousculés, des points de ventes fermés n’ont pas s’est creusé, confi rmant l’évolution des usages. MARCHÉ TOTAL 781 M€ + 0,1% 474 M€ 101 M€ 22 M€ 184 M€ Numérique Physique Droits voisins Synchronisation Source : SNEP Les exploitations numériques sont depuis trois ans publicitaires…) fl échissent de 10% affectés eux aussi par maintenant la première source de chiffre d’affaires de la la baisse d’activité et le report des projets audiovisuels. musique, mais les ventes physiques restent signifi catives L’autre incidence négative des circonstances en France. Aux revenus des ventes, s’ajoutent ceux exceptionnelles sur le marché est l’impact de la fermeture générés par la synchronisation et les droits voisins. des magasins et lieux publics sonorisés, conjuguée à la Les revenus issus de la collecte des droits de baisse des revenus publicitaires des médias traditionnels, synchronisation (musique à l’image, fi lms, séries, spots qui provoquent un recul sensible des droits voisins de -19%. -
2017 Annual Report on Form
FORM 20-F 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ‘ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 Or ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ‘ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boétie, 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boétie, 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one ordinary share, par value €2 per share New York Stock Exchange Ordinary shares, par value €2 per share New York Stock Exchange (for listing purposes only) Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2017 was: Ordinary shares: 1,254,019,904 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. -
Annual Report on Form 20-F 2014
FORM 20-F 2014 FORM 20-F 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) Ⅺ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ࠚ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or Ⅺ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or Ⅺ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boetie,´ 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boetie,´ 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one New York Stock Exchange ordinary share, par value e2 per share Ordinary shares, par value e2 per share New York Stock Exchange (for listing purposes only) Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2014 was: Ordinary shares: 1,319,367,445 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. -
PPCO Twist System
Connect. Collaborate. Contribute. NOVEMBER 2016 Sanofi Genzyme: Expanding Beyond Rare Disease Into Specialty Care p. 18 David Meeker, executive VP and head, Sanofi Genzyme Clinical Trials 26 Allergan R&D 30 Biopharma 32 DC Insider 10 How A Chief Medical Officer Why The Company Women In Bio: Looking CEO Corner 12 Changed The Data-sharing Is Focusing On An Through The Glass Ceiling Culture At J&J And Across “Open-Science Platform” Companies To Watch 16 The Industry Global Update 48 Bringing together the best of When it’s YOUR compound, every step matters. www.pfizercentreone.com API DRUG PRODUCT PC1-16-0005-8.25x10.875 in-Mar., 2016 © 2016 Pfizer Inc. All rights reserved. inVentiv Health. Genetically engineered for success in the new pharmaceutical world. inVentiv Health processes and capabilities can accelerate business performance. The fact is, getting a new drug across the fi nish line is hard work every day. But lately, the challenges have increased exponentially. Today, it’s not enough to simply obtain regulatory approval; market success is now as mission-critical as trial success. Smart outsourcing partners begin with the end in mind. That’s why inVentiv purpose-built an organization in which both clinical and commercial work together under one roof as teammates and colleagues, not distant relatives. From early development through product launch, they share knowledge capital, data and insights. Our superior clinical trial design combined with highly effective commercial launch capabilities creates a unique environment in which processes and systems are constantly being challenged and evolved with an eye towards greater effi ciency, higher quality and, of course, getting to market faster. -
Sanofi 1 4.5
DOCUMENT DE RÉFÉRENCE 2017 SOMMAIRE 4 RESPONSABILITÉ SOCIALE, AVERTISSEMENT AU LECTEUR I ENVIRONNEMENTALE CHIFFRES CLÉS III ET SOCIÉTALE 355 ABRÉVIATIONS VI 4.1. Informations sociales 356 4.2. Informations santé, sécurité, environnement 371 4.3. Informations relatives aux 1 engagements sociétaux en faveur du développement durable 386 4.4. Plan de vigilance 400 PRÉSENTATION DE SANOFI 1 4.5. Note méthodologique sur le reporting des données 403 1.1. Principales informations relatives à 4.6. Rapport de l’organisme tiers la société 2 indépendant 407 1.2. Gouvernement d’entreprise 8 4.7. Tableau des indicateurs des entités juridiques france 410 2 5 ACTIVITÉ DE SANOFI 77 SANOFI ET SES ACTIONNAIRES 413 2.1. Historique et évolution de la société 79 5.1. Sanofi en bourse 414 2.2. Présentation de l’activité de Sanofi 79 5.2. L’information aux actionnaires 417 2.3. Organisation de l’entreprise 128 2.4. Investissements – principaux établissements 129 2.5. Litiges 133 6 2.6. Événements récents 136 PERSONNES RESPONSABLES, 3 ATTESTATION ET TABLES DE CONCORDANCE 421 6.1. Personne responsable RAPPORT DE GESTION, du document de référence 422 ÉTATS FINANCIERS ET 6.2. Attestation du responsable du document de référence INFORMATIONS FINANCIÈRES contenant un rapport financier COMPLÉMENTAIRES 137 annuel 422 3.1. Rapport de gestion relatif à 6.3. Personnes responsables l’exercice 2017 138 du contrôle des comptes 422 3.2. Rapport de la direction de Sanofi 6.4. Rapport des commissaires sur le contrôle interne relatif à aux comptes sur les prévisions l’information financière 203 de bénéfice net des activités par action 423 3.3. -
Sanofi Fires Viehbacher After Fall out with Board
OTC07-11-14p1_OTC15/11/2005 p1&24 05/11/2014 09:07 Page 1 7November 2014 COMPANY NEWS 3 Bayertakes leading spot 3 Sanofi fires Viehbacher in ChinawithDihon deal BoehringersaysnotoOmegabuy 3 GSKhints at Consumer divestments 4 afterfall out with board Merck waves goodbye to 5 Consumer Care business hris Viehbacher,chief executive officer Bayertargets critical mass 6 in Consumer Cof Sanofi, has been firedafter the firm’s board of directors concluded that his “man- Nasacortdrives salesforward 7 at Sanofi agement style was not adequate”. Oriola wantsafairprice 8 In asurprise move,the board of the French for itsRussian operations companyannounced it had “decided unani- BioGaiareports a 9 mously” to remove Viehbacher after six years double-digitsales rise at the helm. Celesioputsfaith in 11 “The group needs to pursue its development new leadership team with amanagement aligning the teams, harness- Pfizer expects Lipitortrialresults 12 ing talent and focusing on execution with aclose in 2015 and confident co-operation with the board,” Sanofistated, adding that its chairman, Serge GENERAL NEWS 13 Weinberg, would takecharge while it search- ed for achief executive. Most Germans have 13 Expanding on the rationale behind the deci- used homoeopathy sion, Weinbergsaid that the board was“strongly Chris Viehbacher has left Sanofi after the board Health Canada approves 16 dissatisfied” with Viehbacher’sability to work Aspirin heart-attack claim criticised his management style with board members to examine the company’s Germans reject OTCguidance 16 strategy “in aconfident manner”. (OTC bulletin,27February 2009, page 1). Australia settooverhaul 17 “The fluidity of the relationship between Acquisitions were central to Viehbacher’s TGAmedicines regulation the chief executive officer and the board was expansion strategy,with the companysnapping MARKETING NEWS 18 inadequate,”herevealed. -
Marseille Tourisme
1 MARSEILLE Dossier de presse 2021 3 2021 DOSSIER DE PRESSE >> SOMMAIRE 3 3 EDITO 4 MARSEILLE EN QUELQUES CHIFFRES 5 MARSEILLE, VILLE CONNECTÉE 6-7 MARSEILLE FACE CAMÉRA 8-9 MARSEILLE, PORT DE CROISIÈRE 10 MARSEILLE, PARCOURS VILLAGEOIS 11-13 MARSEILLE, VILLE D’AFFAIRES 14-15 LES INCONTOURNABLES 16 26 SIÈCLES D’HISTOIRE : DE MASSALIA À MARSEILLE 17 LE PARC NATIONAL DES CALANQUES 18-19 MARSEILLE, DES IDÉES VERTES ! 20-21 EUROMÉDITERRANÉE, BUSINESS DISTRICT 22-23 ART, PATRIMOINE ET EXPÉRIENCES 24-29 SHOPPING À MARSEILLE 30-31 LES TRADITIONS MARSEILLAISES 32-35 MARSEILLE À L’HEURE DE L’APÉRO 36-37 À TABLE ! 38-41 PLANÈTE MARS, PLANÈTE RAP ! 42-43 CITY GUIDE 44-45 MARSEILLE ALENTOURS 46-47 INFOS PRATIQUES 48 edito Qualifiée comme l’une des villes européennes les plus MARSEILLE, incontournables, Marseille la belle, l’incandescente, la DESTINATION PHARE sulfureuse s’ouvre sur le monde, joue de contrastes DU SUD DE LA FRANCE saisissants et de paradoxes fascinants ; riche de son patrimoine et de ses traditions, Marseille n’en est pas moins Marseille a toujours su se visionnaire et n’a de cesse de se remettre en question, de réinventer pour faire face se faire, de se défaire aussi. aux nouveaux enjeux et aux Au-delà des frontières, elle consiste en un melting-pot de situations les plus inédites, avec cultures, de couleurs, de langages, d’histoires et de forces. l’appui essentiel de son Office Métropolitain de Tourisme et Parce qu’elle fédère tous les publics et rayonne à des Congrès, pour porter ses l’international, la ville accueille depuis 2013 de plus en couleurs au plus haut et garantir plus de rendez-vous sportifs, culturels et institutionnels : un accueil optimal ! Capitale européenne de la Culture 2013, puis, ville hôte de l’Euro 2016 de Football, Capitale européenne du Sport en Cette année, Marseille continue 2017, et hôte de la biennale MANIFESTA en 2020.. -
Annual Report on Form 20-F 2018
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boétie, 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boétie, 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one ordinary share, par value€2 per share NASDAQ Global Select Market Ordinary shares, par value€2 per share NASDAQ Global Select Market* Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2018 was: Ordinary shares: 1,245,454,385 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. -
Sanofi R&D Chief Zerhouni
Scrip Asks... IO Roundtable Expert View Do experts see orphan drug pricing Five companies talk about their place New products are set to shake the coming under pressure over the next in immuno-oncology (p10) hemophilia market – but convincing five years? (p4) payers will be a challenge (p14) 10 March 2017 No. 3844 Scripscrip.pharmamedtechbi.com Pharma intelligence | informa consultant to Sanofi; it gained steam when he joined Sanofi in his present position. “I structured the strategy for Sanofi in two phases. The first phase was how do we build a pipeline to be delivered in 2015, 2016, 2017 when we had loss of exclusiv- ity on key products, with Lantus being the last major drug after Plavix and others that lost their patents. The goal was how to do it without breaking the bank,” Zerhouni told Scrip in a recent interview. That initial revamp involved overhauling the pipeline and trimming 19 Phase II and Phase III programs from Sanofi’s R&D pipe- line between 2009 and 2012. Some of the programs missed Phase II endpoints. Oth- ers were discontinued because the value Elias Zerhouni proposition wasn’t there from either the patient or payer perspective. “I modified the strategy in a big way, by putting development first: we have to Sanofi R&D Chief Zerhouni: take care of development and underneath all that, start to fix research, not the other way around. Most heads of R&D, are heads How I’m Doing More With Less of R&D; I said, ‘No, I want to be a head of Elias Zerhouni says Sanofi’s ongoing R&D revamp has produced improved D&R,’ rather than R&D at Sanofi,” Zerhouni innovative results with controlled spending, in part by emphasizing cutting- explained. -
2020 Transparency Report
2020 transparency report SOCIÉTÉ CIVILE DES PRODUCTEURS PHONOGRAPHIQUES [PHONOGRAPHIC PRODUCERS SOCIETY] SCPP – Société Civile des Producteurs Phonographiques [Phonographic Producers Society] General Shareholders' Meeting of 24 June 2021 2020 activity report I. p.6-17 1 / Collections p.11 2 / Distributions p.12 3 / Grants p.12 4 / Grants in the event of non-compliance by distributors and special financial aid p.14 5 / Combating piracy p.14 6 / Communication and institutional relations p.14 7 / Current period p.15 Conclusion 2020 financial report II. p.18-65 1 / Collecting and distributing p.22 2 / Account cut-off p.28 3 / Annual financial statements 2020 p.38 5 4 contents Miscellaneous information III. p.66-71 1 / Number of refusals to grant an operating license p.69 2 / Description of the legal structure and of the governance of the SCPP p.69 3 / List of the entities that the SCPP controls in terms of article l.233-16 of the French Commercial Code p.69 4 / Total amount of remunerations paid to people mentioned in the first paragraph of article l.323-13 of the INTELLECTUAL PROPERTY CODE p.69 5 / Uses of the deducted amounts for the purposes of social, cultural or educational services p.70 6 / Report of the CMO audit committee p.70 Appendices IV. p.72-123 Appendix 1 Organisational chart p.75 Appendix 2 Members of the committee and of the board p.77 Appendix 3 Supervisory Board p.79 Appendix 4 Grants approved by the SCPP in 2020 p.81 Appendix 5 Activity report of the Anti-piracy Uni p.117 Appendix 6 Activity report of the communications department p.121 2020 I. -
Schweizer Hitparade
Jawsh 685 & Jason Derulo 1 Savage Love (Laxed - Siren Beat) 111W -/SME Master KG feat. Burna Boy & Nomcebo 2 Zikode Schweizer Hitparade 29W Jerusalema (Remix) Top 100 Singles -/WMS 30.08.2020 Capital Bra x Cro 3 Frühstück in Paris NEU -/UNI BTS 4 Dynamite NEU -/ORC Harry Styles 5 Watermelon Sugar 318W -/SME 21 8 8W Apache 207 - Bläulich -/SME 22 16 16W Vize & Tom Gregory - Never Let Me Dow n -/KNM DaBaby feat. Roddy Ricch 23 NEU Bausa x Juju - 2012 -/WMS 6 Rockstar 24 19 55W Tones And I - Dance Monkey -/WMS 419W -/UNI 25 20 15W Zoe Wees - Control -/UNI 26 21 6W Kygo x Tina Turner - What's Love Got To Do With It -/SME 27 23 10W Tw ocolors - Lovefool -/UNI Jul, Sch, Naps, Kofs, Elams, Solda, 28 22 17W Mark Forster - Übermorgen -/SME 29 27 3W KitschKrieg feat. Jamule - Unterw egs -/WMS 7 Houari & Soso Maness 30 26 20W Black Eyed Peas / Ozuna + J. Rey Soul - Mamacita -/SME 40 2W Bande organisée 31 46 2W Internet Money & Gunna feat. Don Toliver & Nav - Lemonade -/UNI -/BED 32 48 5W Jason Derulo - Take You Dancing -/WMS 33 29 15W Michael Patrick Kelly - Beautiful Madness -/SME The Weeknd 34 24 2W Miley Cyrus - Midnight Sky -/SME 8 Blinding Lights 35 31 8W Rocco Hunt x Ana Mena - A un passo dalla luna -/SME 36 30 5W J Balvin / Dua Lipa / Bad Bunny / Tainy - Un día (One Day) -/UNI 639W -/UNI 37 NEU Jamule x Chilla - 13 -/UNI 38 28 22W Surf Mesa feat. Emilee - ILY (I Love You Baby) -/UNI Drake feat.